Analysts fell to the sidelines weighing in on Vapotherm (VAPO – Research Report) and Nektar Therapeutics (NKTR – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Vapotherm (VAPO)
In a report released yesterday, Marie Thibault from BTIG maintained a Hold rating on Vapotherm. The company’s shares closed last Thursday at $0.95, close to its 52-week low of $0.46.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
Vapotherm has an analyst consensus of Moderate Sell, with a price target consensus of $0.50.
See today’s best-performing stocks on TipRanks >>
Nektar Therapeutics (NKTR)
Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Nektar Therapeutics yesterday and set a price target of $6.00. The company’s shares closed last Thursday at $2.96, close to its 52-week low of $1.99.
According to TipRanks.com, Goldstein ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Nektar Therapeutics has an analyst consensus of Hold, with a price target consensus of $5.50, implying an 82.7% upside from current levels. In a report issued on February 21, SVB Securities also maintained a Hold rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VAPO:
